CXCR4 and neoplasm: A study conducted by D'Alterio et al. [68] demonstrated that CXCR4 antagonists could reshape tumor microenvironment favoring access of T effector and reducing regulatory T cells to intensify the efficacy of anti-programmed death 1 therapy.